Home > Boards > US Listed > Biotechs > Lexicon Genetics (LXRX)

News: $LXRX Lexicon Realigns Business Around Research and

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
whytestocks Member Profile
Member Level 
Followed By 107
Posts 14,757
Boards Moderated 2
Alias Born 06/04/18
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/17/2020 7:23:07 AM
Results From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Sci... GlobeNewswire Inc. - 11/16/2020 10:01:39 PM
Lexicon Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference GlobeNewswire Inc. - 11/16/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/30/2020 5:11:39 PM
Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update GlobeNewswire Inc. - 10/29/2020 6:00:10 AM
Lexicon Pharmaceuticals to Host Third Quarter 2020 Financial Results Conference Call and Webcast on October 29, 2020 GlobeNewswire Inc. - 10/27/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/29/2020 7:14:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/24/2020 7:13:15 AM
Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness GlobeNewswire Inc. - 9/23/2020 6:43:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/11/2020 4:12:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/8/2020 5:03:21 PM
Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics GlobeNewswire Inc. - 9/8/2020 4:05:10 PM
Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients... GlobeNewswire Inc. - 9/4/2020 8:00:10 AM
Lexicon Pharmaceuticals to Participate in the Citi 15ᵗʰ Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtu... GlobeNewswire Inc. - 9/3/2020 6:00:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 6:00:51 AM
GTCR and TerSera Therapeutics Announce Acquisition of Xermelo PR Newswire (US) - 8/3/2020 7:25:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/30/2020 7:19:01 AM
Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program GlobeNewswire Inc. - 7/30/2020 7:15:10 AM
Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO GlobeNewswire Inc. - 7/30/2020 7:10:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/30/2020 7:05:27 AM
Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update GlobeNewswire Inc. - 7/30/2020 7:00:10 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 7/29/2020 5:08:32 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/29/2020 4:57:55 PM
Lexicon Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call and Webcast on July 30, 2020 GlobeNewswire Inc. - 7/23/2020 7:00:10 AM
Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes GlobeNewswire Inc. - 7/21/2020 7:00:10 AM
whytestocks Member Level  Thursday, 07/30/20 09:15:11 PM
Re: None
Post # of 641 
News: $LXRX Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain Sale of XERMELO to TerSera to Yield Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract C...

Find out more LXRX - Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences